The real‐world, long‐term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study
Dupilumab is associated with a reduced risk of a wide array of systemic and cutaneous infections. This agent might be preferred in patients with susceptibility to infections.
Authors
- Mariam Abdelghaffar (ORCID: https://orcid.org/0009-0001-7643-0061)
- Ralf Joachim Ludwig (ORCID: https://orcid.org/0000-0002-1394-1737)
- Katja Bieber (ORCID: https://orcid.org/0000-0002-3855-6683)
- Khalaf Kridin (ORCID: https://orcid.org/0000-0001-9971-9151)
- Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
Institutions
- Bar-Ilan University (IL)
- Royal College of Surgeons in Ireland - Bahrain (BH)
- Western Galilee Hospital (IL)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2025-05-25
- DOI
- https://doi.org/10.1111/jdv.20724
- Citations
- 8
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 16.04